Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 201

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 201
---
 to its stockholders and that Liminatus’s fair market value was at least 80% of the balance of the funds in the Trust Account (excluding any taxes payable). Accordingly, investors will be relying solely on the judgment of the Iris Board in valuing Liminatus, and the Iris Board may not have properly valued Liminatus. As a result, the terms may not be fair from a financial point of view to Iris’s stockholders. The lack of a fairness opinion may also lead an increased number of Iris’s stockholders to vote against the Business Combination or demand redemption of their Iris Class A Common Stock, which could potentially impact Iris’s ability to consummate the Business Combination.

<div align='center'>87</div>

TABLE OF CONTENTS

### UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION
Defined terms included below have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus, unless defined below. As used in this unaudited pro forma condensed combined financial information, “Liminatus” refers to Liminatus Pharma, LLC, a company incorporated under the laws of Delaware, and “Iris” refers to Iris Acquisition Corp (formerly Tribe Capital Growth Corp I) prior to the Business Combination.

The unaudited pro forma combined financial information has been prepared in accordance with Article 11 of Regulation S-X and presents the combination of the historical financial information of Iris and Liminatus, adjusted to give effect to the Business Combination and the other events contemplated by the Business Combination Agreement. Unless otherwise indicated or the context otherwise requires, references to the “Combined Company” refer to Iris Parent Holding Corp. (“ParentCo”), a Delaware company, and its consolidated subsidiaries after giving effect to the Business Combination.

The unaudited pro forma combined balance sheet as of September 30, 2024 combines the historical balance sheets of Iris and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on September 30, 2024. The unaudited pro forma combined statement of operations for the nine months ended September 30, 2024 and year ended December 31, 2023, combines the historical statements of operations of Iris and Liminatus on a pro forma basis as if the Business Combination and the other events contemplated by the Business Combination Agreement had been consummated on January 1, 2023, the beginning of the earliest period presented.

The unaudited pro forma combined